Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop binding antibodies against viral proteins over a few weeks. The serum dilution required to inhibit viral infection by half is called NT50 and is in the range of 100 to 200 within about a month of symptom onset. However, in some cases, the titers are undetectable, while in others, they may be over 10,000.
A new study by researchers at the Fred Hutchinson Cancer Research Center and the University of Washington and published on the preprint server medRxiv* in August 2020 deals with the changes in neutralizing antibodies in the following months.
